Fredun Pharmaceuticals Ltd

Fredun Pharmaceuticals Ltd has a debt-to-equity ratio of 1.19, indicating a moderate level of leverage in its capital structure. The company's liquidity is assessed as medium, with a current ratio of 1.3, suggesting it has sufficient short-term assets to cover its short-term liabilities, but with limited excess. However, the company's operating cash flow is negative at -290.63 million INR, which may raise concerns about its ability to fund operations from internal cash flows. In terms of profitability, the company's return on equity (ROE) is 13.96%, which is relatively strong, and its return on assets (ROA) is 4.05%, indicating that it is generating a moderate return on its asset base. These figures should be compared to the industry median to determine if the company is outperforming or underperforming its peers. The company's net income of 197.39 million INR and operating income of 475.31 million INR suggest it is profitable, but the gross profit of 1.06 billion INR indicates that the company is facing significant cost pressures. Fredun Pharmaceuticals Ltd operates through several segments, including Generics, Pet Care, Nutraceuticals, Cosmeceuticals, and Mobility. The Generics segment is marketed under the Fredun Gx brand, while the Pet Healthcare segment operates under the Freossi brand. The Nutraceutical Division is under the Fredun Nutrition brand, and the Cosmeceuticals Division operates under the Bird N Beauty (BNB) and Beautyfred brands. The Mobility Division, operating under Chuu Balm, BraceOn, NebOn, and DigiOn, caters to the ortho rehabilitation aids and pain management market. The company's revenue is concentrated in these segments, and there is no indication of significant geographic diversification in the provided data. The company's growth trajectory is not explicitly detailed in the provided data, but the outlook for the current fiscal year and the next fiscal year should be analyzed to determine if the company is expected to grow or contract. The company's revenue history and the numeric deltas provided in the outlook will be crucial in assessing its future performance. The risk assessment for Fredun Pharmaceuticals Ltd indicates a medium liquidity risk and a low dilution risk. The company's key flags include a negative net cash position after subtracting total debt, which may impact its financial stability. The dilution potential is low, and the company has not made any adjustments to its valuations that would suggest a need for additional capital. Recent events, such as filings and transcripts, are not detailed in the provided data. However, the company's financial performance and risk factors should be monitored to assess any potential changes in its business environment.